{
    "clinical_study": {
        "@rank": "105874", 
        "acronym": "HEPASIL", 
        "arm_group": [
            {
                "arm_group_label": "Group C: RIB + Peg-IFN", 
                "arm_group_type": "Active Comparator", 
                "description": "Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 \u03bcg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved"
            }, 
            {
                "arm_group_label": "Group B:Legalon\u00ae SIL + RIB + Peg-IFN", 
                "arm_group_type": "Experimental", 
                "description": "Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 \u03bcg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 \u03bcg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 \u03bcg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)"
            }, 
            {
                "arm_group_label": "Group A: Legalon\u00ae SIL + RIB", 
                "arm_group_type": "Experimental", 
                "description": "Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore whether silibinin plus ribavirin with/without\n      peg-interferon can be more effective than the peg-interferon plus ribavirin based standard\n      of care (SoC) in the treatment of patients infected with hepatitis C virus genotype 4."
        }, 
        "brief_title": "Randomized Study for the Assessment of Silibinin (Legalon\u00ae SIL) in the Treatment of na\u00efve Genotype 4 Patients With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be willing to give written informed consent\n\n          -  Male and female patients; age between 21 and 45 years inclusive\n\n          -  Chronic hepatitis C infection with genotype 4 confirmed by genotypic testing at\n             screening or within 6 months of screening period\n\n          -  Patients eligible to be treated with RBV and Peg-IFN as per the instructions present\n             in their prescribing information documents\n\n          -  No history of prior interferon therapy (treatment na\u00efve)\n\n          -  Detectable HCV-RNA levels\n\n          -  Normal BUN and creatinine\n\n          -  Ability to communicate, participate, and comply with the requirements of the entire\n             study\n\n        Exclusion Criteria:\n\n          -  Liver transplant patients\n\n          -  Co-Infection with HIV and/or HBV\n\n          -  ALT >10-fold the upper limit of normal i.e. > 400 U/L\n\n          -  Evidence of hepatocellular carcinoma (HCC)\n\n          -  Fibroscan\u00ae at screening with a score \u2265 14.5 kPa\n\n          -  Evidence of liver disease due to causes other than chronic HCV infection\n\n          -  Evidence of poorly controlled diabetes (defined as HbA1c > 8%)\n\n          -  History of alcohol or drug abuse within the last 12 months\n\n          -  History or clinical evidence of liver decompensation, e.g. presence of ascites or\n             encephalopathy, or bleeding from esophageal varices\n\n          -  Serum albumin levels < 3.2 g/dL\n\n          -  INR > 1.3 N\n\n          -  Total Bilirubin levels > 2.0 mg/dL unless explained by Gilbert's disease\n\n          -  Platelet Count < 100,000 \u00b5L\n\n          -  Absolute Neutrophil counts < 1500  \u00b5L (mm3)\n\n          -  Active or suspected non-hepatic malignancy or history of malignancy within the last 5\n             years\n\n          -  Body Mass Index < 16 or > 35 kg/m2\n\n          -  Females of childbearing potential:\n\n               -  Pregnancy (i.e. positive urine pregnancy test at screening) or lactation\n\n               -  Failure to agree to practice adequate contraception methods (e.g. oral\n                  contraceptives, intra-uterine device (IUD), transdermal contraceptive patch)\n\n          -  Male patients not vasectomized, who do not agree to abstain from intercourse or who\n             do not use a condom"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871662", 
            "org_study_id": "LEG-SIL-2-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group B:Legalon\u00ae SIL + RIB + Peg-IFN", 
                    "Group A: Legalon\u00ae SIL + RIB"
                ], 
                "description": "Silibinin 20 mg/Kg/day", 
                "intervention_name": "Legalon\u00ae SIL (Silibinin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group C: RIB + Peg-IFN", 
                    "Group B:Legalon\u00ae SIL + RIB + Peg-IFN"
                ], 
                "description": "1.5 \u00b5g/kg once-weekly", 
                "intervention_name": "Pegylated interferon alfa2b", 
                "intervention_type": "Drug", 
                "other_name": "PEG-INTRON\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Group C: RIB + Peg-IFN", 
                    "Group B:Legalon\u00ae SIL + RIB + Peg-IFN", 
                    "Group A: Legalon\u00ae SIL + RIB"
                ], 
                "description": "At weight-based dose 800-1400 mg/day (BID, OS)", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "REBETOL\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Reaferon", 
                "Silymarin", 
                "Silybin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HCV", 
            "Hepatitis C"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "Al-Manial University Hospital, Kasr El-Aini Faculty Medicine, Cairo University"
            }, 
            "investigator": {
                "last_name": "Gamal Esmat, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon\u00ae SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of na\u00efve Genotype 4 Patients With Chronic Hepatitis C", 
        "overall_contact": {
            "email": "massimo.damato@rottapharm.com", 
            "last_name": "Massimo D'Amato, MD", 
            "phone": "+39 039 7390319"
        }, 
        "overall_official": [
            {
                "affiliation": "Al-Manial University Hospital, Kasr El-Aini Faculty Medicine, Cairo University, Egypt", 
                "last_name": "Gamal Esmat, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Maryland School of Medicine,Baltimore, USA", 
                "last_name": "Samer El-Kamary, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Egypt: Ministry of Health and Population", 
                "Egypt: Institutional Review Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the proportion of patients with Sustained Virological Response (SVR), i.e. undetectable HCV-RNA level lasting for 24 weeks after the completion of the study treatment course.", 
            "measure": "Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after the end of treatment (e.g. at week 49 or 73)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871662"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients with Rapid Viral Response (RVR), i.e. undetectable HCV-RNA levels 4 weeks after the beginning of the study treatment course.", 
                "measure": "Undetectable HCV-RNA", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the beginning of the study treatment"
            }, 
            {
                "description": "Number and percentage of patients with Early Viral Response (EVR), i.e. HCV-RNA decrease \u2265 2 log10 IU/mL 12 weeks after the beginning of the study treatment course", 
                "measure": "HCV-RNA decrease \u2265 2 log10 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the beginning of the study treatment"
            }, 
            {
                "description": "Proportion of patients with End Of Treatment (EOT) Response, i.e. undetectable HCV-RNA levels at the end of the study treatment (e.g. at the end of treatment at week 25 or 49)", 
                "measure": "Undetectable HCV-RNA", 
                "safety_issue": "No", 
                "time_frame": "At the end of study treatment (e.g. at week 25 or 49)"
            }, 
            {
                "description": "Proportion of patients with a normalization of Serum Alanine Aminotransferase (ALT <40 U/L) values 4 weeks after the beginning of study treatment, at EOT and at 24 weeks after the completion of the study treatment course;", 
                "measure": "Normalization of Serum Alanine Aminotransferase", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after the beginning of study treatment, at EOT and at 24 weeks after the completion of the study treatment"
            }, 
            {
                "measure": "Number of Participants with adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks after the end of treatment  (e.g. up to week 49 or 73)"
            }
        ], 
        "source": "Rottapharm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rottapharm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}